Focus on the journey of innovative drugs from the laboratory to clinical practice
Gather a seasoned‑R&D team and cutting‑edge technology platforms to empower efficient new‑drug research and development
2026-07-09
Fushi Biotechnology’s FS-207 tablets received clinical trial approval from the National Medical Products Administration
In April 2026, FS-207 tablets, a Class 1 innovative drug independently developed by Fushi Biologics, officially received an implicit clinical trial license (IND approval) from the China National Medical Products Administration (NMPA) and is intended to be developed for the treatment of microsatellite instability-high (MSI-H) advanced solid tumors.
More